The Attention Deficit Hyperactivity Disorder Market is expected to grow at the registered CAGR of 6.9% during the forecast period, 2022-2027.
The attention deficit hyperactivity disorder (ADHD) market is significantly impacted as a result of the COVID-19 pandemic, governments from various countries are taking steps to combat attention deficit hyperactivity disorder (ADHD) in children. According to the study titled "Behavioral Implications of the Covid-19 Process for Autism Spectrum Disorder, and Individuals' Comprehension of and Reactions to the Pandemic Conditions" published in the Frontier in Psychiatry in November 2020, during the Covid-19 outbreak, symptoms of children with attention deficit hyperactivity disorder (ADHD) worsened significantly. Due to the stress caused by the COVID-19 pandemic, patients with attention deficit hyperactivity disorder (ADHD) have become more vulnerable. Thus, the attention deficit hyperactivity disorder market is significantly impacted by the COVID-19.
During the forecast period, the global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to grow due to an increase in the prevalence of the disorder. For instance, as per a February 2021 published study, titled, “The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis”, the prevalence of persistent adult ADHD was 2.58% and that of symptomatic adult ADHD was 6.76%, translating to 139.84 million and 366.33 million affected adults in 2020 globally. Thus, rising in the burden of ADHD expected to rise in demand for its treatment anticipated to boost the market over the forecast period.
Furthermore, the growing emphasis on research and development is resulting in the development of effective ADHD treatments, which is contributing to market growth. For Instance, according to the study titled “Neurofunctional and behavioral measures associated with fMRI-Neurofeedback learning in adolescents with Attention-Deficit/Hyperactivity Disorder” published in the NeuroImage Clinical in May 2020, a larger trial with 100 children with ADHD was funded by the Medical Research Council for GBP 1.3 million. New collaborations with the National Institute of Mental Health and Dresden University were also formed as a result of the work. Since then, the team has received funding (roughly GBP 2 million from the National Institute for Health Research, Action Medical Research) to test other brain-based therapies in ADHD, including non-invasive brain stimulation treatments like transcranial direct current stimulation and stimulation of the trigeminal nerve, which controls facial sensations. Such a development in treatment option for ADHD treatment expected to boost the market over the forecast period.
The ADHD market is expected to grow due to a rise in public awareness about mental health and increased government funding. The rising number of people suffering from a variety of mental health disorders, including attention-deficit/hyperactivity disorder (ADHD), has drew the attention of governments all over the world, forcing them to take action. As per the Regional Development Australia updates in July 2021, in 2021-22, the New South Wales (NSW) Government has contributed USD 1.8 million funding for the ADHD pilot program, with a total investment of USD 7.7 million for trial a new model of care and management for children with behavioural issues including attention-deficit hyperactivity disorder (ADHD) in regional NSW over four years.
Moreover, during the forecast period, key companies focusing on research and development in the treatment of attention deficit hyperactivity disorder (ADHD) therapeutics are expected to drive the global attention deficit hyperactivity disorder (ADHD) therapeutics market. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a subsidiary in the United States, reported positive top-line results from phase 3 clinical trials evaluating the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.
Thus, the aforementioned factors are likely to drive the growth of the market during the forecast period. However, less availability of non-stimulants ADHD drug and underdiagnosis of ADHD, therefore these factors are acting as some of the major restraints to the studied market.
The stimulant segment dominated the ADHD market and is expected to continue to do so throughout the forecast period. This is due to the high demand for these drugs, which stems from their efficacy in treating symptoms of attention deficit hyperactivity disorder, ongoing clinical trials, and government support for the use of stimulants in the treatment of mental health disorders. Stimulant drugs include Amphetamine, Methylphenidate, Lisdexamfetamine, and Dexmethylphenidate.
Amphetamines (e.g., Adderall) and methylphenidate (e.g., Ritalin and Concerta) are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder (ADHD). The study titled "A cognitive neuroscience review of the etiology of ADHD" published by the Association of Child and Adolescent Mental Health in January 2022, describe that stimulant works quickly, and there is also a reduction in overall impulsivity and ADHD symptoms in two hours. It also reported that stimulants are the most effective treatment for ADHD patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of ADHD boost the segment growth over the forecast period.
Furthermore, rise in clinical studies to evaluate the effectiveness of the stimulant drug in the ADHD treatment anticipated to drive the segment over the forecast period. For instance, as pet the ClinicalTrial.gov updates on July 2021, the study titled "A Pivotal Efficacy Trial to Evaluate HLD200 (methylphenidate) in Children With ADHD in a Classroom Setting" under the development phase III by Ironshore Pharmaceuticals and Development, Inc. Hence, increasing in number of drug development will expected to rise in the accessibility of ADHD therapeutics
and thus anticipated to boost the segment growth.
Moreover, approval and commercialization of new drugs by market players are also expected to play a crucial role in driving market growth over the coming years. For instance, in March 2021, Azstarys (KemPharma) received Food and Drug Administration approval for central nervous system stimulant for the treatment of ADHD.It is one of the first drug with the combination of dexmethylphenidate and serdexmethylphenidate. Such approvals are propelling the growth of market segment.
Thus, the aforementioned factors are likely to drive the growth of the segment during the forecast period.
North America dominates the ADHD market over the forecast period. This is due to the large number of drug prescriptions written each year, the increased number of product launches, and the increased collaboration among players to improve market penetration and product development.
Furthermore, rising in the prevalence of ADHD in the country is anticipated to drive the market over the forecast period. According to the Centers for Diseases Control and Prevention in September 2021, 8.8% of people have been diagnosed with ADHD at some point in their lives. Moreover, 13.6 million visits to doctors' offices were made with attention deficit disorder as the primary diagnosis.
In addition, increasing spending on the treatment of ADHD in the United States with rising prescription rates is expected to boost the market. According to the study titled "Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective" published in the Managed Care and Specialty Pharmacy in February 2022, in the United States, an estimated 8,716,972 adults have ADHD, resulting in a total societal excess cost of USD 122.8 billion (USD 14,092 per adult). Thus rise in healthcare spending anticipated to drive the market growth over the forecast period.
Additionally, approval and commercialization of new drugs are also expected to play a key role in driving market growth in the coming years. For instance, in April 2021, the Food and Drug Administration approved Qelbree (KELL'-bree for treating attention deficit hyperactivity disorder in children ages 6 to 17.
Furthermore, in February 2021, Noven Pharmaceuticals, Inc., has submitted a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) for patients six years and older.
Thus, the aforementioned factors are likely to drive the growth of the marker during the forecast period.
The attention deficit hyperactivity disorder market is moderately competitive owing to the presence of multiple players. The players in the market are adopting strategies like product innovation, mergers, and acquisitions in order to expand their product portfolio and expand their geographic reach and primarily to stay competitive in the market. Some of the vendors in the market are Eli Lily & Company, Pfizer, Johnson & Johnson Services, LLC, Lupin, Shire, Mallinckrodt, Prude Pharma L.P., NEOS Therapeutics Inc. and among Other
This product will be delivered within 2 business days.
The attention deficit hyperactivity disorder (ADHD) market is significantly impacted as a result of the COVID-19 pandemic, governments from various countries are taking steps to combat attention deficit hyperactivity disorder (ADHD) in children. According to the study titled "Behavioral Implications of the Covid-19 Process for Autism Spectrum Disorder, and Individuals' Comprehension of and Reactions to the Pandemic Conditions" published in the Frontier in Psychiatry in November 2020, during the Covid-19 outbreak, symptoms of children with attention deficit hyperactivity disorder (ADHD) worsened significantly. Due to the stress caused by the COVID-19 pandemic, patients with attention deficit hyperactivity disorder (ADHD) have become more vulnerable. Thus, the attention deficit hyperactivity disorder market is significantly impacted by the COVID-19.
During the forecast period, the global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to grow due to an increase in the prevalence of the disorder. For instance, as per a February 2021 published study, titled, “The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis”, the prevalence of persistent adult ADHD was 2.58% and that of symptomatic adult ADHD was 6.76%, translating to 139.84 million and 366.33 million affected adults in 2020 globally. Thus, rising in the burden of ADHD expected to rise in demand for its treatment anticipated to boost the market over the forecast period.
Furthermore, the growing emphasis on research and development is resulting in the development of effective ADHD treatments, which is contributing to market growth. For Instance, according to the study titled “Neurofunctional and behavioral measures associated with fMRI-Neurofeedback learning in adolescents with Attention-Deficit/Hyperactivity Disorder” published in the NeuroImage Clinical in May 2020, a larger trial with 100 children with ADHD was funded by the Medical Research Council for GBP 1.3 million. New collaborations with the National Institute of Mental Health and Dresden University were also formed as a result of the work. Since then, the team has received funding (roughly GBP 2 million from the National Institute for Health Research, Action Medical Research) to test other brain-based therapies in ADHD, including non-invasive brain stimulation treatments like transcranial direct current stimulation and stimulation of the trigeminal nerve, which controls facial sensations. Such a development in treatment option for ADHD treatment expected to boost the market over the forecast period.
The ADHD market is expected to grow due to a rise in public awareness about mental health and increased government funding. The rising number of people suffering from a variety of mental health disorders, including attention-deficit/hyperactivity disorder (ADHD), has drew the attention of governments all over the world, forcing them to take action. As per the Regional Development Australia updates in July 2021, in 2021-22, the New South Wales (NSW) Government has contributed USD 1.8 million funding for the ADHD pilot program, with a total investment of USD 7.7 million for trial a new model of care and management for children with behavioural issues including attention-deficit hyperactivity disorder (ADHD) in regional NSW over four years.
Moreover, during the forecast period, key companies focusing on research and development in the treatment of attention deficit hyperactivity disorder (ADHD) therapeutics are expected to drive the global attention deficit hyperactivity disorder (ADHD) therapeutics market. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a subsidiary in the United States, reported positive top-line results from phase 3 clinical trials evaluating the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.
Thus, the aforementioned factors are likely to drive the growth of the market during the forecast period. However, less availability of non-stimulants ADHD drug and underdiagnosis of ADHD, therefore these factors are acting as some of the major restraints to the studied market.
Key Market Trends
Stimulant Drug Type Segment is Expected to Projected Significant Growth Over the Forecast Period.
The stimulant segment dominated the ADHD market and is expected to continue to do so throughout the forecast period. This is due to the high demand for these drugs, which stems from their efficacy in treating symptoms of attention deficit hyperactivity disorder, ongoing clinical trials, and government support for the use of stimulants in the treatment of mental health disorders. Stimulant drugs include Amphetamine, Methylphenidate, Lisdexamfetamine, and Dexmethylphenidate.
Amphetamines (e.g., Adderall) and methylphenidate (e.g., Ritalin and Concerta) are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder (ADHD). The study titled "A cognitive neuroscience review of the etiology of ADHD" published by the Association of Child and Adolescent Mental Health in January 2022, describe that stimulant works quickly, and there is also a reduction in overall impulsivity and ADHD symptoms in two hours. It also reported that stimulants are the most effective treatment for ADHD patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of ADHD boost the segment growth over the forecast period.
Furthermore, rise in clinical studies to evaluate the effectiveness of the stimulant drug in the ADHD treatment anticipated to drive the segment over the forecast period. For instance, as pet the ClinicalTrial.gov updates on July 2021, the study titled "A Pivotal Efficacy Trial to Evaluate HLD200 (methylphenidate) in Children With ADHD in a Classroom Setting" under the development phase III by Ironshore Pharmaceuticals and Development, Inc. Hence, increasing in number of drug development will expected to rise in the accessibility of ADHD therapeutics
and thus anticipated to boost the segment growth.
Moreover, approval and commercialization of new drugs by market players are also expected to play a crucial role in driving market growth over the coming years. For instance, in March 2021, Azstarys (KemPharma) received Food and Drug Administration approval for central nervous system stimulant for the treatment of ADHD.It is one of the first drug with the combination of dexmethylphenidate and serdexmethylphenidate. Such approvals are propelling the growth of market segment.
Thus, the aforementioned factors are likely to drive the growth of the segment during the forecast period.
North America Holds a Significant Share in the Market and Expected to do Same during the Forecast Period
North America dominates the ADHD market over the forecast period. This is due to the large number of drug prescriptions written each year, the increased number of product launches, and the increased collaboration among players to improve market penetration and product development.
Furthermore, rising in the prevalence of ADHD in the country is anticipated to drive the market over the forecast period. According to the Centers for Diseases Control and Prevention in September 2021, 8.8% of people have been diagnosed with ADHD at some point in their lives. Moreover, 13.6 million visits to doctors' offices were made with attention deficit disorder as the primary diagnosis.
In addition, increasing spending on the treatment of ADHD in the United States with rising prescription rates is expected to boost the market. According to the study titled "Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective" published in the Managed Care and Specialty Pharmacy in February 2022, in the United States, an estimated 8,716,972 adults have ADHD, resulting in a total societal excess cost of USD 122.8 billion (USD 14,092 per adult). Thus rise in healthcare spending anticipated to drive the market growth over the forecast period.
Additionally, approval and commercialization of new drugs are also expected to play a key role in driving market growth in the coming years. For instance, in April 2021, the Food and Drug Administration approved Qelbree (KELL'-bree for treating attention deficit hyperactivity disorder in children ages 6 to 17.
Furthermore, in February 2021, Noven Pharmaceuticals, Inc., has submitted a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) for patients six years and older.
Thus, the aforementioned factors are likely to drive the growth of the marker during the forecast period.
Competitive Landscape
The attention deficit hyperactivity disorder market is moderately competitive owing to the presence of multiple players. The players in the market are adopting strategies like product innovation, mergers, and acquisitions in order to expand their product portfolio and expand their geographic reach and primarily to stay competitive in the market. Some of the vendors in the market are Eli Lily & Company, Pfizer, Johnson & Johnson Services, LLC, Lupin, Shire, Mallinckrodt, Prude Pharma L.P., NEOS Therapeutics Inc. and among Other
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eli Lily & Company
- Pfizer
- Johnson & Johnson
- Lupin
- Takeda Pharmaceutical (Shire PLC)
- Mallinckrodt
- Perdue Pharma L.P. (Adlon Therapeutics)
- NEOS Therapeutics Inc.
- KemPharm, Inc.
- Novartis AG
- Aurobindo pharma
- Otsuka Group
- Hisamitsu Group (Noven Pharmaceutical Inc.)
Methodology
LOADING...
